



EUREOS

*European Society of Eosinophilic
Oesophagitis*

EUREOS ANNUAL REPORT

2022–2023

ADDRESS

Alfredo Lucendo

Hospital General de Tomelloso, Spain

Committee's Office

www.eureos.online

info.eureos@gmail.com

www.centerview.ch

EDITORIAL

DEAR COLLEAGUES,



This year EUREOS celebrates its tenth anniversary. Throughout this decade our common project has been consolidating, gaining scope and recognition. With a constantly increasing number of members, the regions through which they are distributed, and with already consolidated projects, it is time to take stock of the year.

At the same time, now is also time to outline our society's strategy for the future. EUREOS must continue to consolidate as an essential reference in the production of knowledge and provision of education and scientific exchange at the highest quality around EoE, and to expand them to other eosinophilic GI diseases. Our organization must be increasingly transversal, capable of meeting expectations and supporting our members' projects, as well as being a reliable partner for our corporate members. We do not forget our commitment to patients and their organizations, whose best care is our reason for being.

I would like to recognize the work of the previous presidents and all the executive committees who have brought us to this day. We are grateful to the members and collaborators who strive to advance our projects. We will continue to advance knowledge about eosinophilic GI diseases as a single, aligned voice in Europe and beyond

Best regards,

A handwritten signature in blue ink, appearing to read 'Alfredo J. Lucendo'.

Alfredo J. Lucendo
President 2021–2025

ABOUT EUREOS

EUREOS is the meeting point for clinicians and researchers to share knowledge on EoE.




The objective of the organization is to establish and maintain a network and a communication platform for physicians and researchers with a specific interest in eosinophilic esophagitis (EoE) and eosinophilic gastro-enteritis and/or eosinophilic colitis in Europe.

STEERING COMMITTEE

The EUREOS steering committee 2022–2023 consists of

- Alfredo Lucendo (President 2021–2025)
- Arjan Bredenoord (Past-President)
- Luc Biedermann (Treasurer)
- Stephan Miehke
- Matteo Ghisa
- Christoph Schlag
- Salvatore Oliva
- Helen Larsson
- Ulrike von Armin

MEMBERS



EUREOS is currently supported by 219 members from 53 different countries worldwide. When it comes to profession, more than half of our members are specialized in adult gastroenterology. We invite all physicians and scientist interested in EoE or wanting to support our work to become a member.

Members can participate in the annual general assembly and play an active role in deciding about future activities of EUREOS.

Membership is free for physicians and scientists.

Furthermore, our members have access to the password-protected member area containing several valuable information and a slide library.

COMMUNICATION PLATFORM

The website is the central communication channel of EUREOS. The EUREOS website consists of two sections directed towards health care professionals and researchers, our main target audience, and patients, respectively.

EOE CONNECT

European Registry of Clinical, Environmental and Genetic Determinants in Eosinophilic Esophagitis

In 2016 EUREOS created an advanced multilingual EoE database with the aim to improve knowledge on epidemiology, its evolving trends, and on its burden to the health systems across Europe. The registry serves as a base for implementation of further prospective collaborative studies and is open to patients from all Europe. To date over 2,700 patients of all ages have been recruited by 51 study sites in 4 European Countries. Detailed research objectives are the following:

- To describe the socio-demographical and clinical characteristics as well as personal antecedents of EoE patients.
- To examine the relationship between time of disease onset, length of diagnostic delay, and disease phenotypes.
- To determine the influence of environmental and genetic factors on the time of onset, natural history and course of EoE.
- To analyse the use, effectiveness, and safety of the different therapeutic interventions in EoE, both in short and long term, using the standardized set of outcomes.
- To examine the burden of disease costs associated with EoE in adults.

EoE CONNECT is run under the patronage of EUREOS with a scientific committee of ten international EoE experts. Contributors, that have added more than 30 patients in the EoE registry, can submit a study request to the scientific committee using the data in the EoE registry. Currently six studies and several UEGW abstracts have been published using the EoE CONNECT database:

- Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry *Pharmacol Ther.* 2020 Sep;52(5):798-807.
- Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. *Clin Gastroenterol Hepatol.* 2020 Dec;18(13):2903-2911.
- Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. *Dig Liver Dis.* 2021 Nov;53(11):1479-1485.
- EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a largescale epidemiological study in Europe *Therap Adv Gastroenterol.* 2022 Feb 2;15:17562848221074204.
- Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe.An analysis of the EoE CONNECT Registry. *United European Gastroenterol J.* 2022 Jun;10(5):507-517.
- Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry. *Dig Liver Dis.* 2023 Mar;55(3):350-359.

EXPERT RECOMMENDATIONS

EUREOS EO E PATIENT FOLLOW UP PROJECT: WHY? WHAT? WHEN?

Uncontrolled inflammation in EoE may lead to complications such as strictures. In daily practice, gastroenterologists face the challenge that symptoms and PROs do not always match histological findings; uncontrolled inflammation and fibrosis are the result. To close this gap, a structured patient follow-up is necessary. Under the patronage of EUREOS in collaboration with TIGERs, the Patient Follow-up Programme was therefore launched by Ulrike von Armin, with the aim of developing international expert recommendations on «why», «how» and «when» to follow-up EoE patients.

- Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations. *Clin Gastroenterol Hepatol.* 2023 Sep;21(10):2526-2533.

The patient-follow up initiative joins the previous projects initiated by EUREOS focusing on essential aspects for clinical practice. The first project in this series was dedicated to the role of PPIs in EoE and was continued with the COREOS Core-Outcome-Set project, both being implemented in collaboration with CEGIR, and EGID Committee of AAAAI.

- A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus *Gastroenterology.* 2021 Sep;161(3):778-784
- Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus *Gastroenterology.* 2021 Sep;161(3):778-784.

- Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus *Gastroenterology*. 2021 Sep;161(3):748-755.
- Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS) *J Allergy Clin Immunol*. 2021 Jul 6;S0091-6749(21)01059-9.
- Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis *Gut*. 2016 Mar;65(3):524-31.

RENEWAL OF EUROPEAN GUIDELINES ON EOE

The current European Guidelines on diagnosis and management of EoE date back to 2017. The diagnostic and therapeutic armamentarium have developed since; thus the guidelines need to be renewed. Under the patronage of EUROES this process has been initiated by Alfredo Lucendo. Publication of the renewed Guidelines is expected for 2024.

EDUCATION

INTERNATIONAL EVENTS

As in previous years, the fifth annual scientific EUREOS EoE Symposium took place as in-person event in parallel to UEGW 2022.

Main topics were:

- Epidemiology and natural history of eosinophilic esophagitis
(Marijn Warners, Netherlands)
- Long term maintenance therapy
(Javier Molina-Infante, Spain)
- Advanced emerging therapeutic options
(Luc Biedermann, Switzerland)

ONLINE EDUCATION PLATFORM



In 2022, EUREOS launched EUREOS Library (<https://eureos.nubwebinar.com/>) an online Education Platform for healthcare professionals with content exclusively focused on EoE and other eosinophilic gastrointestinal disorders.

EUREOS Library aims to spread and share high-quality and updated scientific content produced by EUREOS members, groups and committees consisting of courses, symposia, webinars and podcasts that cover all aspects of EoE, EGID and concomitant diseases.

EUREOS Library allows to gain CME accreditation through specific modules offered, after completing a teaching activity and to check the achievement of learning goals.

Due to the cross-sectional nature of the EoE and the other EGIDs, courses are suitable for gastroenterologists, pediatricians, allergists, ENT specialists, and specialists working in digestive endoscopy, regardless of their familiarity with EoE. In addition, the course is aimed at primary care family doctors and pediatricians, as well as nurses, dieticians and nutritionists, and researchers interested in this disease.

PATIENT RELATIONS

EoE Day 2023

As in 2022, EUREOS supported the European EoE Day. on 22 May 23 with several activities, such as participation in patient webinars on that day. For more information about patient-related topics, please visit our website.

ACKNOWLEDGEMENT

We thank our sponsors for their long standing financial support:

PLATINUM SPONSORS



GOLD SPONSORS



SPONSORS



